Literature DB >> 14527911

Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital.

Chun-Nan Yeh1, Wei-Chen Lee, Miin-Fu Chen, Pei-Kwei Tsay.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a common disease in Taiwan. A high incidence of recurrence after hepatectomy is the most important cause of unsatisfactory results after resection of HCC. This study aimed to determine the clinicopathologic factors for predicting survival >5 years without recurrence in HCC patients treated with hepatectomy.
METHODS: The clinical features of 46 patients with surgically resected HCC who survived >5 years without recurrence (group A) were reviewed. Also, comparison was made with the clinical features and factors influencing the outcome of 1046 cases of resected HCC who survived <5 years both with and without recurrence and for >5 years with recurrence (group B).
RESULTS: Of 1092 cases of surgically resected HCC, 46 (4.5%) survived >5 years without recurrence. Univariate analysis revealed that absence of vascular invasion, satellite lesions, low histological grading of HCC, a lower rate of underlying liver cirrhosis, wider resection margins, and an uneventful postoperative course were frequent in group A patients compared with group B patients. Moreover, multivariate stepwise logistic regression analysis identified an absence of satellite lesions and an uneventful postoperative course as the two main independently significant predictors of HCC patients undergoing hepatectomy with long-term disease-free survival. The 1-, 3-, 5-, and 10-year survival rates of group A patients were 100%, 100%, 100%, and 84.1%, whereas those of group B patients were 73.5%, 47.9%, 29.0%, and 21.2%, respectively.
CONCLUSIONS: An absence of satellite lesions and an uneventful postoperative course are the two main independent predictors for long-term disease-free survival in HCC patients undergoing hepatic resection.

Entities:  

Mesh:

Year:  2003        PMID: 14527911     DOI: 10.1245/aso.2003.09.012

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 2.  Current and future treatments for hepatocellular carcinoma.

Authors:  Alexander Schlachterman; Willie W Craft; Eric Hilgenfeldt; Avir Mitra; Roniel Cabrera
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

Review 3.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

4.  Disease-free survival after hepatic resection in hepatocellular carcinoma patients: a prediction approach using artificial neural network.

Authors:  Wen-Hsien Ho; King-Teh Lee; Hong-Yaw Chen; Te-Wei Ho; Herng-Chia Chiu
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

5.  The actual five-year survival rate of hepatocellular carcinoma patients after curative resection.

Authors:  Jae Gil Lee; Chang Mu Kang; Joon Seong Park; Kyung Sik Kim; Dong Sup Yoon; Jin Sub Choi; Woo Jung Lee; Byong Ro Kim
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

6.  Recurrence Patterns After Hepatectomy With Very Narrow Resection Margins for Hepatocellular Carcinoma.

Authors:  Chih-Hsien Cheng; Yin Lai; Hao-Chien Hung; Jin-Chiao Lee; Yu-Chao Wang; Tsung-Han Wu; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Kun-Ming Chan; Wei-Chen Lee
Journal:  Front Surg       Date:  2022-07-12

7.  Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma.

Authors:  Chun-Nan Yeh; See-Tong Pang; Tsung-Wen Chen; Ren-Ching Wu; Wen-Hui Weng; Miin-Fu Chen
Journal:  BMC Cancer       Date:  2009-07-15       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.